Immunotherapy candidate targeting the metastatic process
PHASE 1 COMPLETED
MVA-BN Brachyury is a novel cancer immunotherapy candidate, designed to induce a robust T-cell immune response against brachyury, a tumor-associated antigen that is overexpressed in major solid tumor indications, as well as several rare, ultra-orphan cancer indications. Brachyury is reported to play a key role in the metastasis and progression of tumors.
Tumors that overexpress brachyury are believed to be highly resistant to current therapies and are associated with decreased survival rates.
While Bavarian Nordic retains worldwide commercial rights to MVA-BN Brachyury in multiple cancer indications, the clinical development is sponsored by the NCI with whom we continue to work to evaluate the product candidate. Clinical Phase 2 studies are expected to be initiated in 2017.